Company News: Manhattan Research, Merck

Share this article:

Pharma and healthcare market research firm Manhattan Research has released the latest version of its ePharma Physician v11.0 study, which indicates that since June 2011, 38% of the physicians polled have seen a pharma or biotech sales rep use an iPad or other tablet during a face-to-face meeting over the course of the past year. The study's findings also suggest that marketers have yet to optimize the interactive features and capabilities of tablet devices to achieve the most efficient and customized discussion with physicians about their products. Key highlights of the newest edition of the ePharma Physician study have found that enthusiasm for tablet-hocking reps varies by specialty, with general surgeons, anesthesiologists, and OB/GYNs, to name a few, making up the specialty groups that find tablets to be most effective during office visits, as well as the fact that Pfizer, AstraZeneca, Merck and Abbott make up big-name pharmas leading the way in terms of iPad reach via sales reps.

Merck has lost an overtime pay lawsuit filed on behalf of Schering-Plough sales reps. Federal Judge Janet Bond Arterton has ruled that the administrative exemption under the Fair Labor Standards Act – which relieves employers from paying overtime to executive or administrative employees, and to employees who earn more than $455 per week whose principal duties are to perform non-manual, general business – does not apply to the sales reps at Schering-Plough who initiated the suit.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.